Charco Neurotech raises £500k in seed funding led by Parkwalk Advisors to launch its Parkinson management device.
The seed round was led by Parkwalk Advisors and includes backing from Amadeus Capital Partners, Crista Galli, RCA, and Oxbridge Angels to fund the market launch of the CUE1 device.
Charco Neurotech develops non-invasive wearable medical devices designed to help manage symptoms for people with Parkinson disease. The team brings together designers, engineers, and medical professionals to create accessible health solutions.
Charco Neurotech has secured £500k in a seed financing round led by Parkwalk Advisors through the Imperial College Innovation Fund. Additional participants in the syndicate include Amadeus Capital Partners, Crista Galli, RCA, and Oxbridge Angels.
The capital will support the company as it prepares to launch its CUE1 device in the UK and European markets. The non-invasive wearable technology uses controlled vibrations and companion digital tools to assist with motor tasks and symptom tracking for Parkinson patients.
The investment marks the inaugural deployment from the Imperial College Innovation Fund, highlighting the role of university spinout initiatives in supporting early-stage medical technology ventures originating from academic research ecosystems.
From the founder
"We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials."
Lucy Jung
CEO and Co-founder at Charco Neurotech
Investor perspective
"Since launching ICIF in the summer, we have met hundreds of amazing founders and I am delighted that first investment will go to support such an enthusiastic and capable team making such an impact in patients’ lives."
Brijesh Roy
Investment Manager, Mercia Fund Management
Use of funds
- 01Expand into international markets
Investors
Categories
About the company
Charco Neurotech
Charco Neurotech develops wearable technology to manage Parkinson symptoms.